Comparative Study of Fluorodeoxyglucose Positron Emission Tomography and Magnetic Resonance Imaging for the Detection of Spinal Bone Marrow Infiltration in Untreated Patients with Multiple Myeloma

References

• Bartl R, Frisch B, Diem H, Mundel M, Nagel D, Lamerz R, et al. Histologic, biochemical, and clinical parameters for monitoring multiple myeloma. Cancer 1991; 68: 2241–50
   PubMed Web of Science ®Google Scholar
• Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, et al. Treatment of multiple myeloma. Blood 2004; 103: 20–32
   PubMed Web of Science ®Google Scholar
• Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4: 379–98
   PubMedGoogle Scholar
• Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842–54
   PubMed Web of Science ®Google Scholar
• Rahmouni A, Divine M, Mathieu D, Golli M, Dao TH, Jazaerli N, et al. Detection of multiple myeloma involving the spine: efficacy of fat-suppression and contrast-enhanced MR imaging. Am J Roentgenol 1993; 160: 1049–52
   Google Scholar
• Angtuaco EJ, Fassas AB, Walker R, Sethi R, Barlogie B. Multiple myeloma: clinical review and diagnostic imaging. Radiology 2004; 231: 11–23
   PubMed Web of Science ®Google Scholar
• Bataille R, Chevalier J, Rossi M, Sany J. Bone scintigraphy in plasma-cell myeloma. A prospective study of 70 patients. Radiology 1982; 145: 801–4
   Google Scholar
• Mariette X, Zagdanski AM, Guermazi A, Bergot C, Arnould A, Frija J, et al. Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J Haematol 1999; 104: 723–9
   PubMed Web of Science ®Google Scholar
• Moulopoulos LA, Dimopoulos MA, Smith TL, Weber DM, Delasalle KB, Libshitz HI, et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 1995; 13: 251–6
   PubMed Web of Science ®Google Scholar
• Tertti R, Alanen A, Remes K. The value of magnetic resonance imaging in screening myeloma lesions of the lumbar spine. Br J Haematol 1995; 91: 658–60
   PubMed Web of Science ®Google Scholar
• Ghanem N, Lohrmann C, Engelhardt M, Pache G, Uhl M, Saueressig U, et al. Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. Eur Radiol 2006; 16: 1005–14
   PubMed Web of Science ®Google Scholar
• Lecouvet FE, Malghem J, Michaux L, Maldague B, Ferrant A, Michaux JL, et al. Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey. Br J Haematol 1999; 106: 35–9
   PubMedGoogle Scholar
• Moulopoulos LA, Dimopoulos MA, Weber D, Fuller L, Libshitz HI, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol 1993; 11: 1311–5
   PubMed Web of Science ®Google Scholar
• Moulopoulos LA, Varma DG, Dimopoulos MA, Leeds NE, Kim EE, Johnston DA, et al. Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. Radiology 1992; 185: 833–40
   PubMed Web of Science ®Google Scholar
• Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. Am J Roentgenol 2005; 184: 1199–204
   PubMed Web of Science ®Google Scholar
• Breyer RJ 3rd, Mulligan ME, Smith SE, Line BR, Badros AZ. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiol 2006; 35: 632–40
   PubMed Web of Science ®Google Scholar
• Durie BG, Waxman AD, D'Agnolo A, Williams CM. Whole body 18F-FDG PET identifies high-risk myeloma. J Nucl Med 2002; 43: 1457–63
   PubMed Web of Science ®Google Scholar
• Jadvar H, Conti PS. Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol 2002; 31: 690–4
   PubMed Web of Science ®Google Scholar
• Kato T, Tsukamoto E, Nishioka T, Yamazaki A, Shirato H, Kobayashi S, et al. Early detection of bone marrow involvement in extramedullary plasmacytoma by whole-body F-18 FDG positron emission tomography. Clin Nucl Med 2000; 25: 870–3
   PubMed Web of Science ®Google Scholar
• Mulligan ME, Badros AZ. PET/CT and MR imaging in myeloma. Skeletal Radiol 2007; 36: 5–16
   Google Scholar
• Nanni C, Zamagni E, Farsad M, Castellucci P, Tosi P, Cangini D, et al. Role of 18F-FDG-PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging 2006; 33: 525–31
   PubMed Web of Science ®Google Scholar
• Schirrmeister H, Bommer M, Buck AK, Müller S, Messer P, Bunjes D, et al. Initial results in the assessment of multiple myeloma using 18F- FDG PET. Eur J Nucl Med Mol Imaging 2002; 29: 361–6
   PubMed Web of Science ®Google Scholar
• Baur A, Stabler A, Nagel D, Lamerz R, Bartl R, Hiller E, et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon?. Cancer 2002; 95: 1334–5
   PubMed Web of Science ®Google Scholar
• Baur A, Stabler A, Bartl R, Lamerz R, Scheidler J, Reiser M. MRI gadolinium enhancement of bone marrow: age-related changes in normals and in diffuse neoplastic infiltration. Skeletal Radiol 1997; 26: 414–8
   Google Scholar
• Schick F. Whole-body MRI at high field: technical limits and clinical potential. Eur Radiol 2005; 15: 946–59
   Google Scholar
• Ricci C, Cova M, Kang Y, Yang A, Rahmouni A, Scott WW, Jr, et al. Normal age-related patterns of cellular and fatty bone marrow distribution in the axial skeleton: MR imaging study. Radiology 1990; 177: 83–8
   PubMed Web of Science ®Google Scholar